Catalyst Biosciences Inc Com (NASDAQ:CBIO)

CAPS Rating: 1 out of 5

A biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system.

CBIO News and Commentary

Caps

How do you think CBIO will perform against the market?

Add Stock to CAPS Watchlist

All Players

111 Outperform
120 Underperform
 

All-Star Players

31 Outperform
31 Underperform
 

Wall Street

6 Outperform
1 Underperform
 

Top CBIO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

headyinvestor (59.03)
Submitted April 11, 2012

This stock can't possibly get beat up anymore.... (knocks on wood)... interesting mechanism of action, figure some movement in the clinical development status will up the price

EtamarL (< 20)
Submitted October 15, 2009

Here's a classic, I'm afraid. This stock is up 500% on some good milestone news. Their drug still has a way to go before final approval for marketing, and the stock is already valued 17 times earnings, bringing it to small cap range of $500M.At half… More

CBIO VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about CBIO.

Recs

0
Member Avatar rhallbick (97.17) Submitted: 3/26/2018 8:58:17 AM : Outperform Start Price: $26.72 CBIO Score: +5.68

In Aug 2015, South San Francisco-based Catalyst Biosciences completed a reverse merger with a beleaguered, NASDAQ-listed, North Carolina biotech named Targacept, and Catalyst Biosciences became a publicly traded company.

This small cap biopharmaceutical has been developing coagulation factors to promote blood clotting in hemophilia patients. Collaborator Isu Abxis of Korea has fully integrated capabilities for clinical development and manufacturing, and is currently testing Catalyst's CB 2679d (aka ISU304), a next-generation coagulation Factor IX variant. CB 2679d has shown a longer duration of action than other Factor IX products, and has the potential to be the first approved subcutaneous injection treatment for hemophilia B (instead of the traditional route of lengthy IV infusions). The Phase 1/2 proof-of-concept study in patients with severe hemophilia B has been underway in Korea since mid-2017, and reports of favorable top line data from the testing has been pushing the stock price up. In Jun 2017, the European Commission and in Sep 2017, the U.S. Food and Drug Administration (FDA) granted orphan drug designations for CB 2679d. Isu holds an option to exclusively commercialize Catalyst's factor IX candidates in Korea, while Catalyst retains development and commercial ownership rights of the program outside of Korea.

Oct 31, 2017: . . 10-Q reports 4,310,561 shares
Dec 22, 2017: . . Public stock offering of 1,105,263 shares at $9.50 per share.
Jan 19, 2018: . . 6,366,604 shares reported outstanding
Feb 15, 2018: . . Public stock offering of 3,382,352 shares at $34.00 per share

CBIO stock closed on Feb 12, 2018 at $35.60, before the latest equity offering was announced. The stock price proceeded to drop nearly 30% over the next couple of weeks from this dilution. It was originally expected that the December equity funding would be sufficient to carry the company through to 2019. The surprise Feb equity offering raised an additional $100 million for CBIO's coffers. Perhaps means they are not in any discussions to be acquired, and have therefore funded themselves for further development and trials for many years. Prior cash burn rate has been about $20 million per year.

Price: $26.72 . | . Annualized Dividend: $0 . | . Dividend Yield: 0%

Recs

0
Member Avatar toyotamoney (< 20) Submitted: 12/23/2013 7:25:45 PM : Outperform Start Price: $43.47 CBIO Score: -82.81

Cheap

Recs

0
Member Avatar rknapton (29.89) Submitted: 8/22/2013 5:05:19 PM : Underperform Start Price: $51.07 CBIO Score: +105.75

Short. Biopharma with dwindling revenues.

Leaderboard

Find the members with the highest scoring picks in CBIO.

Score Leader

BravoBevo

BravoBevo (99.97) Score: +861.08

"For I know the thoughts that I think toward you, says the Lord, thoughts of peace and not of evil, to give you a future and a hope. Then you will call upon Me and go and pray to Me, and I will listen to you. And you will seek Me and find Me, when you search for Me with all your heart." Jeremiah 29:11-13 . . . "For My thoughts are not your thoughts, nor are your ways My ways, says the Lord. For as the heavens are higher than the earth, so are My ways higher than your ways, and My thoughts than your thoughts." Isaiah 55:8-9 . . . "How precious also are Your thoughts to me, O God! How great is the sum of them! If I should count them, they would be more in number than the sand; when I awake, I am still with You." Psalm 139:17-18 . . .

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille2 99.42 8/29/2017 Outperform 5Y $3.45 +671.88% +7.51% +664.37 0 Comment
PAGEBOY54 96.39 9/13/2017 Outperform 5Y $3.65 +629.59% +5.31% +624.28 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Under5 < 20 9/13/2017 Outperform 5Y $3.80 +600.79% +5.19% +595.60 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 70.71 11/13/2017 Outperform 5Y $5.10 +422.55% +1.82% +420.72 0 Comment
extranatty 98.04 2/23/2017 Outperform 5Y $6.70 +297.46% +11.02% +286.44 0 Comment
herztical 27.59 7/22/2009 Underperform 5Y $90.42 -70.55% +178.22% +248.77 0 Comment
gildid 40.26 8/17/2009 Underperform 3Y $134.21 -80.16% +168.13% +248.29 0 Comment
markProxy 30.94 8/17/2009 Underperform 1Y $139.80 -80.95% +167.32% +248.27 0 Comment
WeathermanGR13 98.94 8/17/2009 Underperform 5Y $139.80 -80.95% +167.32% +248.27 0 Comment
dormantaccount < 20 8/17/2009 Underperform 3M $139.80 -80.95% +167.32% +248.27 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 84.82 11/15/2011 Underperform 3W $79.45 -66.48% +108.58% +175.06 0 Comment
trackglobalhunte < 20 11/9/2011 Outperform NS $109.95 -30.01% -0.81% -29.20 12/20/2011 @ $76.95 0 Comment
TrackMKMPartners 94.66 7/27/2011 Outperform NS $213.19 -87.51% +100.14% -187.65 0 Comment
TrackNeedham 88.87 5/6/2011 Outperform NS $374.55 -66.64% -6.55% -60.09 11/8/2011 @ $124.95 0 Comment
TrackDeutscheSec 87.76 11/19/2010 Outperform NS $236.77 -88.75% +119.33% -208.09 0 Comment
TrackJimCramer 84.82 11/6/2009 Outperform 3W $301.65 -62.56% +17.69% -80.24 11/16/2011 @ $112.95 0 Comment
TrackNeedham 88.87 10/17/2009 Outperform NS $367.20 +9.72% +22.12% -12.40 3/31/2011 @ $402.90 0 Comment
TrackOppenheimer 74.38 9/16/2009 Outperform NS $165.44 -83.90% +150.57% -234.48 0 Comment
TrackLadenburg < 20 8/4/2009 Outperform NS $155.25 -19.52% +26.11% -45.63 11/8/2011 @ $124.95 0 Comment
TrackEveillard 96.21 3/31/2008 Outperform NS $77.34 -65.57% +108.88% -174.45 1 Comment
TrackLeerinkSwan 95.21 9/20/2007 Outperform NS $96.86 -72.51% +80.81% -153.31 0 Comment
TrackLazardCapit 83.05 1/9/2007 Outperform NS $97.07 -72.57% +97.53% -170.09 0 Comment

Featured Broker Partners